Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$6.16
At close: Jun 16 EDT
$6.17
0.010000.16%
Pre-Market: 5:12 AM EDT
Comments
Loading...
Verve Therapeutics Analyst Ratings and Price Targets | NASDAQ:VERV | Benzinga
Verve Therapeutics Inc has a consensus price target of $31.13 based on the ratings of 10 analysts. The high is $62 issued by BMO Capital on July 18, 2022. The low is $13 issued by Goldman Sachs on December 15, 2022. The 3 most-recent analyst ratings were released by Guggenheim, Canaccord Genuity, and HC Wainwright & Co. on April 15, 2025, April 15, 2025, and April 14, 2025, respectively. With an average price target of $29.33 between Guggenheim, Canaccord Genuity, and HC Wainwright & Co., there's an implied 375.42% upside for Verve Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Canaccord Genuity
HC Wainwright & Co.
RBC Capital
Stifel
1calculated from analyst ratings
Analyst Ratings for Verve Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/15/2025 | Buy Now | — | Cantor Fitzgerald | Rick Bienkowski28% | — | Upgrade | Neutral → Overweight | Get Alert |
| 04/15/2025 | Buy Now | 288.98% | Guggenheim | Etzer Darout49% | $18 → $24 | Maintains | Buy | Get Alert |
| 04/15/2025 | Buy Now | 532.09% | Canaccord Genuity | Whitney Ijem59% | $32 → $39 | Maintains | Buy | Get Alert |
| 04/14/2025 | Buy Now | 305.19% | HC Wainwright & Co. | Mitchell Kapoor46% | $15 → $25 | Maintains | Buy | Get Alert |
| 03/25/2025 | Buy Now | — | Guggenheim | Seamus Fernandez63% | — | Reiterates | Buy → Buy | Get Alert |
| 03/25/2025 | Buy Now | 143.11% | HC Wainwright & Co. | Mitchell Kapoor46% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2025 | Buy Now | 143.11% | RBC Capital | Luca Issi46% | $17 → $15 | Maintains | Outperform | Get Alert |
| 02/28/2025 | Buy Now | 143.11% | HC Wainwright & Co. | Mitchell Kapoor46% | $14 → $15 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 418.64% | Canaccord Genuity | Whitney Ijem59% | $29 → $32 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 175.53% | RBC Capital | Luca Issi46% | $20 → $17 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | 126.9% | HC Wainwright & Co. | Mitchell Kapoor46% | $15 → $14 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 370.02% | Canaccord Genuity | Whitney Ijem59% | $30 → $29 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 143.11% | HC Wainwright & Co. | Mitchell Kapoor46% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 224.15% | RBC Capital | Luca Issi46% | $25 → $20 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | 143.11% | HC Wainwright & Co. | Mitchell Kapoor46% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 548.3% | Stifel | Dae Gon Ha49% | $56 → $40 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 467.26% | RBC Capital | Luca Issi46% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 09/13/2023 | Buy Now | 256.56% | Cantor Fitzgerald | Rick Bienkowski28% | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 08/29/2023 | Buy Now | 256.56% | Cantor Fitzgerald | Rick Bienkowski28% | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 08/15/2023 | Buy Now | 791.41% | Guggenheim | Seamus Fernandez63% | $56 → $55 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 402.43% | Credit Suisse | Richard Law48% | → $31 | Reiterates | Neutral → Neutral | Get Alert |
| 06/16/2023 | Buy Now | 370.02% | Canaccord Genuity | Whitney Ijem59% | → $29 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 467.26% | RBC Capital | Luca Issi46% | → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 04/13/2023 | Buy Now | 370.02% | Canaccord Genuity | Whitney Ijem59% | → $29 | Initiates | → Buy | Get Alert |
| 02/01/2023 | Buy Now | 240.36% | Cantor Fitzgerald | Rick Bienkowski28% | → $21 | Initiates | → Neutral | Get Alert |
| 12/15/2022 | Buy Now | 110.7% | Goldman Sachs | Andrea Tan40% | → $13 | Initiates | → Sell | Get Alert |
| 11/08/2022 | Buy Now | 467.26% | RBC Capital | Luca Issi46% | $42 → $35 | Maintains | Outperform | Get Alert |
| 10/06/2022 | Buy Now | 677.96% | Credit Suisse | Richard Law48% | → $48 | Initiates | → Neutral | Get Alert |
| 08/25/2022 | Buy Now | 807.62% | Stifel | Dae Gon Ha49% | $32 → $56 | Upgrade | Hold → Buy | Get Alert |
| 07/18/2022 | Buy Now | 904.86% | BMO Capital | Kostas Biliouris35% | $48 → $62 | Maintains | Outperform | Get Alert |
| 06/17/2022 | Buy Now | 677.96% | BMO Capital | Kostas Biliouris35% | → $48 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Verve Therapeutics (VERV) stock?
The latest price target for Verve Therapeutics (NASDAQ:VERV) was reported by Cantor Fitzgerald on April 15, 2025. The analyst firm set a price target for $0.00 expecting VERV to fall to within 12 months (a possible -100.00% downside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Verve Therapeutics (VERV)?
The latest analyst rating for Verve Therapeutics (NASDAQ:VERV) was provided by Cantor Fitzgerald, and Verve Therapeutics upgraded their overweight rating.
When was the last upgrade for Verve Therapeutics (VERV)?
The last upgrade for Verve Therapeutics Inc happened on April 15, 2025 when Cantor Fitzgerald raised their price target to N/A. Cantor Fitzgerald previously had a neutral for Verve Therapeutics Inc.
When was the last downgrade for Verve Therapeutics (VERV)?
There is no last downgrade for Verve Therapeutics.
When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on April 15, 2025 so you should expect the next rating to be made available sometime around April 15, 2026.
Is the Analyst Rating Verve Therapeutics (VERV) correct?
While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a upgraded with a price target of $0.00 to $0.00. The current price Verve Therapeutics (VERV) is trading at is $6.17, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
